🇺🇸 FDA
Pipeline program

Fosmetpantotenate

024PKAN15004

Phase 3 small_molecule terminated

Quick answer

Fosmetpantotenate for Pantothenate Kinase-Associated Neurodegeneration is a Phase 3 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Travere Therapeutics
Indication
Pantothenate Kinase-Associated Neurodegeneration
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials